News | May 28, 2021
Bharat Biotech signs MoU with GCVC for COVID Vaccine
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
As of 2nd May 2021, the Government has provided more 16.54 crore COVID-19 vaccine doses to States/UTs free of cost
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
These media reports are based on incorrect facts and are without any basis.
The country has constantly worked with the spirit of public-private partnership
Subscribe To Our Newsletter & Stay Updated
